The Manufacturers Life Insurance Company purchased a new position in Puma Biotechnology, Inc. (NASDAQ:PBYI – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 17,765 shares of the biopharmaceutical company’s stock, valued at approximately $58,000.
Several other hedge funds and other institutional investors also recently made changes to their positions in PBYI. Affinity Asset Advisors LLC purchased a new stake in shares of Puma Biotechnology during the second quarter valued at approximately $815,000. SG Americas Securities LLC bought a new position in shares of Puma Biotechnology during the first quarter valued at $57,000. O Shaughnessy Asset Management LLC lifted its holdings in shares of Puma Biotechnology by 127.7% during the first quarter. O Shaughnessy Asset Management LLC now owns 77,081 shares of the biopharmaceutical company’s stock valued at $409,000 after purchasing an additional 43,229 shares in the last quarter. American Century Companies Inc. boosted its position in shares of Puma Biotechnology by 98.5% during the second quarter. American Century Companies Inc. now owns 738,902 shares of the biopharmaceutical company’s stock valued at $2,409,000 after buying an additional 366,653 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its holdings in Puma Biotechnology by 99.9% in the 2nd quarter. Assenagon Asset Management S.A. now owns 140,205 shares of the biopharmaceutical company’s stock worth $457,000 after buying an additional 70,060 shares in the last quarter. Hedge funds and other institutional investors own 61.29% of the company’s stock.
Insider Buying and Selling
In other Puma Biotechnology news, Director Michael Patrick Miller sold 23,358 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $3.49, for a total transaction of $81,519.42. Following the completion of the sale, the director now directly owns 47,000 shares of the company’s stock, valued at approximately $164,030. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 23.70% of the stock is currently owned by insiders.
Puma Biotechnology Stock Performance
Puma Biotechnology (NASDAQ:PBYI – Get Free Report) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. The company had revenue of $47.10 million for the quarter, compared to the consensus estimate of $43.99 million. Puma Biotechnology had a return on equity of 18.36% and a net margin of 4.01%. During the same quarter in the prior year, the company earned $0.05 earnings per share. On average, equities analysts forecast that Puma Biotechnology, Inc. will post 0.25 earnings per share for the current year.
Analysts Set New Price Targets
Several equities analysts have issued reports on the stock. StockNews.com cut shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 13th. HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Puma Biotechnology in a research report on Friday, August 2nd.
Check Out Our Latest Report on PBYI
Puma Biotechnology Profile
Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Further Reading
- Five stocks we like better than Puma Biotechnology
- Investing in Travel Stocks Benefits
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- What is the Shanghai Stock Exchange Composite Index?
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- Compound Interest and Why It Matters When Investing
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Want to see what other hedge funds are holding PBYI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Puma Biotechnology, Inc. (NASDAQ:PBYI – Free Report).
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.